肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理

2020-03-15 国外肿瘤科相关专家小组（统称） J Thorac Oncol. 2020 Mar;15(3):324-343.

非小细胞肺癌

2020年3月，亚洲胸部肿瘤研究组(ATORG)发布了优化Ⅲ期非小细胞肺癌的管理共识声明，Ⅲ期非小细胞肺癌（NSCLC）是一种异质性疾病，其最佳治疗方法仍具挑战。本文主要针对Ⅲ期NSCLC的诊断和治疗

中文标题：

2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理

英文标题：

Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC.

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2020-03-15

简要介绍：

2020年3月，亚洲胸部肿瘤研究组(ATORG)发布了优化Ⅲ期非小细胞肺癌的管理共识声明，Ⅲ期非小细胞肺癌（NSCLC）是一种异质性疾病，其最佳治疗方法仍具挑战。本文主要针对Ⅲ期NSCLC的诊断和治疗（包括手术治疗、化疗、放疗、靶向治疗和免疫治疗）的相关内容提出实践指导。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=dc0a61c00190031e, title=2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理, enTitle=Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC., guiderFrom=J Thorac Oncol. 2020 Mar;15(3):324-343., authorId=0, author=, summary=2020年3月，亚洲胸部肿瘤研究组(ATORG)发布了优化Ⅲ期非小细胞肺癌的管理共识声明，Ⅲ期非小细胞肺癌（NSCLC）是一种异质性疾病，其最佳治疗方法仍具挑战。本文主要针对Ⅲ期NSCLC的诊断和治疗, cover=https://img.medsci.cn/202055/1588681470440_2020535.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sun Mar 15 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年3月，亚洲胸部肿瘤研究组(ATORG)发布了优化Ⅲ期非小细胞肺癌的管理共识声明，Ⅲ期非小细胞肺癌（NSCLC）是一种异质性疾病，其最佳治疗方法仍具挑战。本文主要针对Ⅲ期NSCLC的诊断和治疗（包括手术治疗、化疗、放疗、靶向治疗和免疫治疗）的相关内容提出实践指导。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2184, appHits=101, showAppHits=39, pcHits=923, showPcHits=2100, likes=0, shares=5, comments=5, approvalStatus=1, publishedTime=Tue May 05 20:43:48 CST 2020, publishedTimeString=2020-03-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue May 05 20:24:35 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Fri Jan 05 11:09:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理.pdf)])
2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1078244, encodeId=4dee10e824472, content=xwuxuexue**uexi学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc35713656, createdName=ms9000001410187120, createdTime=Thu Dec 09 00:18:06 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010323, encodeId=dc09101032393, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f32e2382729, createdName=12318330m15暂无昵称, createdTime=Sun Aug 22 15:40:31 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902238, encodeId=1fa1902238af, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Nov 25 18:08:46 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899216, encodeId=f19a899216e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Sat Nov 14 23:12:41 CST 2020, time=2020-11-14, status=1, ipAttribution=)]
    2021-12-09 ms9000001410187120

    xwuxuexue**uexi学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1078244, encodeId=4dee10e824472, content=xwuxuexue**uexi学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc35713656, createdName=ms9000001410187120, createdTime=Thu Dec 09 00:18:06 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010323, encodeId=dc09101032393, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f32e2382729, createdName=12318330m15暂无昵称, createdTime=Sun Aug 22 15:40:31 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902238, encodeId=1fa1902238af, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Nov 25 18:08:46 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899216, encodeId=f19a899216e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Sat Nov 14 23:12:41 CST 2020, time=2020-11-14, status=1, ipAttribution=)]
    2021-08-22 12318330m15暂无昵称

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1078244, encodeId=4dee10e824472, content=xwuxuexue**uexi学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc35713656, createdName=ms9000001410187120, createdTime=Thu Dec 09 00:18:06 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010323, encodeId=dc09101032393, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f32e2382729, createdName=12318330m15暂无昵称, createdTime=Sun Aug 22 15:40:31 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902238, encodeId=1fa1902238af, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Nov 25 18:08:46 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899216, encodeId=f19a899216e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Sat Nov 14 23:12:41 CST 2020, time=2020-11-14, status=1, ipAttribution=)]
    2020-11-25 carolinewy

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1078244, encodeId=4dee10e824472, content=xwuxuexue**uexi学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc35713656, createdName=ms9000001410187120, createdTime=Thu Dec 09 00:18:06 CST 2021, time=2021-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1010323, encodeId=dc09101032393, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f32e2382729, createdName=12318330m15暂无昵称, createdTime=Sun Aug 22 15:40:31 CST 2021, time=2021-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=902238, encodeId=1fa1902238af, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201125/9bc06da0897c428f850caf978dfc127c/ba622673e84b4b3e93af23305ce1415a.jpg, createdBy=da081405396, createdName=carolinewy, createdTime=Wed Nov 25 18:08:46 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=899216, encodeId=f19a899216e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ef92129227, createdName=1361fc5d0em, createdTime=Sat Nov 14 23:12:41 CST 2020, time=2020-11-14, status=1, ipAttribution=)]
    2020-11-14 1361fc5d0em

    学习

    0

相关指南

2019 加拿大共识：渐进性，假进行性和寡转移性非小细胞肺癌

国外肿瘤科相关专家小组（统称） · 2019-02-01

美国国家综合癌症网络非小细胞肺癌指南2019 V1 版更新要点解读

暂未更新 · 2019-01-20

非小细胞肺癌术后辅助治疗中国胸外科专家共识（2018版）

中国抗癌协会肺癌专业委员会 · 2018-10-15

拓展阅读

ASCO指南：IV期非小细胞肺癌的维持治疗（2009）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2011 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识

中华医学会病理学分会 · 2010-01-01

2010ESMO临床实践指南：早期和局部晚期（非转移性）非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南：转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

ASCO临时临床意见：考虑一线使用EGFR-TKI(表皮生长因子受体酪氨酸激酶抑制剂)的晚期非小细胞肺癌病人进行EGFR突变检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2011-04-11